SAB Biotherapeutics (SABS) to Release Earnings on Thursday

SAB Biotherapeutics (NASDAQ:SABS) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($1.16) per share and revenue of $0.12 million for the quarter.

SAB Biotherapeutics Stock Down 7.0 %

Shares of SABS opened at $1.60 on Tuesday. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. SAB Biotherapeutics has a 1 year low of $1.45 and a 1 year high of $5.01. The business’s 50 day simple moving average is $2.19 and its 200-day simple moving average is $2.87.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $12.40.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.